ZLNA ZELLUNA ASA

Zelluna ASA – Disclosure of voting rights of Annual General Meeting

Zelluna ASA – Disclosure of voting rights of Annual General Meeting

Oslo, April 8, 2026: In connection with the Annual General Meeting of Zelluna ASA to be held on April 23, 2026, Anders Tuv, Chair of the Board of Directors, has, as of the date of this announcement, received proxy-based voting rights without voting instructions (discretionary proxies) for 2,308,791 shares, representing 8.79% of the total voting rights in the Company.

The proxies are only valid for the Annual General Meeting on April 23, 2026. Shares for which advance votes have been cast are not included.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Anders Tuv, Chairman of the Board

Email:

Phone:

Namir Hassan, Chief Executive Officer

Email:

Phone:

Geir Christian Melen, Chief Financial Officer

Email:

Phone:



EN
08/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE

Zelluna ASA – Disclosure of voting rights of Annual General Meeting

Zelluna ASA – Disclosure of voting rights of Annual General Meeting Oslo, April 8, 2026: In connection with the Annual General Meeting of Zelluna ASA to be held on April 23, 2026, Anders Tuv, Chair of the Board of Directors, has, as of the date of this announcement, received proxy-based voting rights without voting instructions (discretionary proxies) for 2,308,791 shares, representing 8.79% of the total voting rights in the Company. The proxies are only valid for the Annual General Meeting on April 23, 2026. Shares for which advance votes have been cast are not included. This information...

 PRESS RELEASE

Zelluna ASA – Mandatory notification of trade

Zelluna ASA – Mandatory notification of trade Oslo, Norway, 27 March 2026 - Anders Tuv, Managing Director in Radforsk Invest, and Chairperson and co-founder of Zelluna ASA (Zelluna), has today entered into an agreement with Radforsk Investeringsstiftelse (Radforsk) pursuant to which Mr. Tuv has been granted options (the Options) to acquire up to 200,000 shares held by Radforsk in Zelluna. Each Option provides a right to acquire one share in Zelluna from Radforsk at an exercise price of NOK 18.5 per share (subject to customary adjustments). The Options are immediately vested and may be exer...

 PRESS RELEASE

Zelluna to host Capital Markets Update 2026

Zelluna to host Capital Markets Update 2026 Oslo, Norway – 26 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, invites investors, analysts and other stakeholders to attend its Capital Markets Update on 14 April 2026 (11:30–13:00 CET). At the event the company will present progress on its TCR-NK off-the-shelf cell therapy platform and ongoing clinical activities, including perspectives on early clinical data and recent developments in the cell therapy field. The ...

 PRESS RELEASE

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026 Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026.  The General Meeting will be held electronically and all documents related to the Annual General Meeting are available at the Company’s website at  For further information, please contact: Anders Tuv, Chairman of the BoardEmail: Phone: Namir Hassan, Chief Executive OfficerEmail: Phone: Geir Christian Melen, Chief Financial OfficerEmail: Phone:   Attachments ...

 PRESS RELEASE

Zelluna ASA [ZLNA]: Annual Report 2025

Zelluna ASA [ZLNA]: Annual Report 2025 Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2025.  A PDF version of the Annual Report, as well as the report in European Single Electronic Format (ESEF), are attached to this release. The Annual Report is also available on the company's website: This information is subject to the disclosure requirements pursuant to Sectio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch